Literature DB >> 32118195

Ancient species offers contemporary therapeutics: an update on shark VNAR single domain antibody sequences, phage libraries and potential clinical applications.

Hejiao English1,2, Jessica Hong1,2, Mitchell Ho1,2.   

Abstract

The antigen binding variable domain (VNAR) of the shark immunoglobulin new antigen receptor (IgNAR) evolved approximately 500 million years ago and it is one of the smallest antibody fragments in the animal kingdom with sizes of 12-15 kDa. This review discusses the current knowledge of the shark VNAR single domain sequences and ongoing development of shark VNARs as research tools as well as potential therapeutics, in particular highlighting the recent next-generation sequencing analysis of 1.2 million shark VNAR sequences and construction of a large phage displayed shark VNAR library from six naïve adult nurse sharks (Ginglymostoma cirratum). The large phage-displayed VNAR single domain library covers all the four known VNAR types (Types I-IV) and many previously unknown types. Ongoing preclinical development will help define the utility of shark VNAR single domains as a potentially new family of drug candidates for treating cancer and other human diseases.
© The Author(s) 2020. Published by Oxford University Press on behalf of Antibody Therapeutics.

Entities:  

Keywords:  VNAR single domain; antibody engineering; next-generation sequencing; nurse shark (Ginglymostoma cirratum); phage display library

Year:  2020        PMID： 32118195      PMCID： PMC7034638          DOI： 10.1093/abt/tbaa001

Source DB:  PubMed          Journal:  Antib Ther        ISSN： 2516-4236


  59 in total

Review 1.  Antibody repertoire development in cartilaginous fish.

Authors:  H Dooley; M F Flajnik
Journal:  Dev Comp Immunol       Date:  2006       Impact factor: 3.636

2.  In vitro improvement of a shark IgNAR antibody by Qbeta replicase mutation and ribosome display mimics in vivo affinity maturation.

Authors:  George Kopsidas; Anthony S Roberts; Gregory Coia; Victor A Streltsov; Stewart D Nuttall
Journal:  Immunol Lett       Date:  2006-10-16       Impact factor: 3.685

3.  An evolutionarily mobile antigen receptor variable region gene: doubly rearranging NAR-TcR genes in sharks.

Authors:  Michael F Criscitiello; Mark Saltis; Martin F Flajnik
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-20       Impact factor: 11.205

4.  Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma.

Authors:  Nan Li; Haiying Fu; Stephen M Hewitt; Dimiter S Dimitrov; Mitchell Ho
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

5.  The structural analysis of shark IgNAR antibodies reveals evolutionary principles of immunoglobulins.

Authors:  Matthias J Feige; Melissa A Gräwert; Moritz Marcinowski; Janosch Hennig; Julia Behnke; David Ausländer; Eva M Herold; Jirka Peschek; Caitlin D Castro; Martin Flajnik; Linda M Hendershot; Michael Sattler; Michael Groll; Johannes Buchner
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-15       Impact factor: 11.205

6.  Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody.

Authors:  Renae Walsh; Stewart Nuttall; Peter Revill; Danni Colledge; Liza Cabuang; Sally Soppe; Olan Dolezal; Kate Griffiths; Angeline Bartholomeusz; Stephen Locarnini
Journal:  Virology       Date:  2011-01-15       Impact factor: 3.616

7.  Selection of cholera toxin specific IgNAR single-domain antibodies from a naïve shark library.

Authors:  Jinny L Liu; George P Anderson; James B Delehanty; Richard Baumann; Andrew Hayhurst; Ellen R Goldman
Journal:  Mol Immunol       Date:  2006-09-27       Impact factor: 4.407

8.  Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies.

Authors:  Erwin De Genst; Karen Silence; Klaas Decanniere; Katja Conrath; Remy Loris; Jörg Kinne; Serge Muyldermans; Lode Wyns
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

9.  Allosteric inhibition of Aurora-A kinase by a synthetic vNAR domain.

Authors:  Selena G Burgess; Arkadiusz Oleksy; Tommaso Cavazza; Mark W Richards; Isabelle Vernos; David Matthews; Richard Bayliss
Journal:  Open Biol       Date:  2016-07       Impact factor: 6.411

Review 10.  Single domain antibodies: promising experimental and therapeutic tools in infection and immunity.

Authors:  Janusz Wesolowski; Vanina Alzogaray; Jan Reyelt; Mandy Unger; Karla Juarez; Mariela Urrutia; Ana Cauerhff; Welbeck Danquah; Björn Rissiek; Felix Scheuplein; Nicole Schwarz; Sahil Adriouch; Olivier Boyer; Michel Seman; Alexei Licea; David V Serreze; Fernando A Goldbaum; Friedrich Haag; Friedrich Koch-Nolte
Journal:  Med Microbiol Immunol       Date:  2009-06-16       Impact factor: 3.402
View more
  14 in total

1.  Production and Purification of Shark and Camel Single-Domain Antibodies from Bacterial and Mammalian Cell Expression Systems.

Authors:  Zhijian Duan; Jesse Buffington; Jessica Hong; Mitchell Ho
Journal:  Curr Protoc       Date:  2022-06

Review 2.  Strategies and Tactics for the Development of Selective Glycan-Binding Proteins.

Authors:  Elizabeth M Ward; Megan E Kizer; Barbara Imperiali
Journal:  ACS Chem Biol       Date:  2021-01-26       Impact factor: 4.634

Review 3.  Perspectives on the development of neutralizing antibodies against SARS-CoV-2.

Authors:  Mitchell Ho
Journal:  Antib Ther       Date:  2020-05-20

Review 4.  Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic.

Authors:  Yaping Sun; Mitchell Ho
Journal:  Antib Ther       Date:  2020-11-24

5.  Camel nanobodies broadly neutralize SARS-CoV-2 variants.

Authors:  Jessica Hong; Hyung Joon Kwon; Raul Cachau; Catherine Z Chen; Kevin John Butay; Zhijian Duan; Dan Li; Hua Ren; Tianyuzhou Liang; Jianghai Zhu; Venkata P Dandey; Negin Martin; Dominic Esposito; Uriel Ortega-Rodriguez; Miao Xu; Mario J Borgnia; Hang Xie; Mitchell Ho
Journal:  bioRxiv       Date:  2021-10-29

6.  A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer.

Authors:  Dan Li; Hejiao English; Jessica Hong; Tianyuzhou Liang; Glenn Merlino; Chi-Ping Day; Mitchell Ho
Journal:  Mol Ther Oncolytics       Date:  2022-02-20       Impact factor: 7.200

7.  Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants.

Authors:  Jessica Hong; Hyung Joon Kwon; Raul Cachau; Catherine Z Chen; Kevin John Butay; Zhijian Duan; Dan Li; Hua Ren; Tianyuzhou Liang; Jianghai Zhu; Venkata P Dandey; Negin P Martin; Dominic Esposito; Uriel Ortega-Rodriguez; Miao Xu; Mario J Borgnia; Hang Xie; Mitchell Ho
Journal:  Proc Natl Acad Sci U S A       Date:  2022-04-27       Impact factor: 12.779

Review 8.  Shark New Antigen Receptor (IgNAR): Structure, Characteristics and Potential Biomedical Applications.

Authors:  Salma Nassor Juma; Xiaoxia Gong; Sujie Hu; Zhengbing Lv; Jianzhong Shao; Lili Liu; Guiqian Chen
Journal:  Cells       Date:  2021-05-08       Impact factor: 6.600

Review 9.  Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments.

Authors:  Annamaria Sandomenico; Jwala P Sivaccumar; Menotti Ruvo
Journal:  Int J Mol Sci       Date:  2020-08-31       Impact factor: 5.923

Review 10.  Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy.

Authors:  Carlos Cruz-Teran; Karthik Tiruthani; Morgan McSweeney; Alice Ma; Raymond Pickles; Samuel K Lai
Journal:  Adv Drug Deliv Rev       Date:  2020-12-09       Impact factor: 17.873
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.